EGFR and colorectal carcinoma: Anti-EGFR (epidermal growth factor receptor) treatments, such as panitumumab or cetuximab monotherapy, or cetuximab in combination with irinotecan or other chemotherapeutic agents, have been tested for their efficacy against KRAS-mutated CRC, with devastating results [51,52,53].